ALMS ALUMIS INC.

Nasdaq www.alumis.com


$ 5.59 $ 0.05 (1 %)    

Monday, 17-Nov-2025 11:48:15 EST
QQQ $ 610.59 $ 4.51 (0.74 %)
DIA $ 471.59 $ 0.73 (0.16 %)
SPY $ 672.54 $ 2.81 (0.42 %)
TLT $ 89.27 $ 0.19 (0.21 %)
GLD $ 374.28 $ 0.28 (0.07 %)
$ 5.52
$ 5.54
$ 5.61 x 277
$ 5.62 x 200
$ 5.46 - $ 5.63
$ 2.76 - $ 10.64
1,721,724
na
576.25M
$ -2.55
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-19-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.96) by 1...

Core News & Articles

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.

Core News & Articles

Alumis (NASDAQ:ALMS) reported quarterly sales of $2.67 million which beat the analyst consensus estimate of $2.00 million by 33...

Core News & Articles

Wells Fargo analyst Derek Archila initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Ta...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.

Core News & Articles

Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immun...

Core News & Articles

- SEC Filing

Core News & Articles

Guggenheim analyst Yatin Suneja reinstates Alumis (NASDAQ:ALMS) with a Buy and announces $18 price target.

Core News & Articles

Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $26 to $25.

Core News & Articles
Alumis Q1 Sales $17.39M
05/14/2025 20:29:21

Alumis (NASDAQ:ALMS) reported $17.39 million in sales this quarter.

Core News & Articles

ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of t...

Core News & Articles

lumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimiz...

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.

Core News & Articles

HC Wainwright & Co. analyst Mitchell Kapoor maintains Alumis (NASDAQ:ALMS) with a Buy and lowers the price target from $...

Core News & Articles

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRI...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION